2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
2seventy bio (Nasdaq: TSVT) has announced it will release its second quarter 2024 financial results on August 7, 2024. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Investors can access the call via webcast on the company's website or register for dial-in details. 2seventy bio is known for developing the first FDA-approved CAR T cell therapy for multiple myeloma. The company's name reflects its mission to work at maximum speed (270 miles per hour) to give cancer patients more time. 2seventy bio focuses on understanding the human body's immune response to tumor cells and translating cell therapies into practice.
2seventy bio (Nasdaq: TSVT) ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 il 7 agosto 2024. L'azienda organizzerà una conferenza telefonica e una trasmissione in webcast alle 8:00 a.m. ET per discutere i risultati. Gli investitori potranno accedere alla chiamata tramite webcast sul sito web dell'azienda o registrarsi per i dettagli della chiamata. 2seventy bio è conosciuta per aver sviluppato la prima terapia CAR T cellulare approvata dalla FDA per il mieloma multiplo. Il nome dell'azienda riflette la sua missione di lavorare alla massima velocità (270 miglia all'ora) per dare ai pazienti affetti da cancro più tempo. 2seventy bio si concentra sulla comprensione della risposta immunitaria del corpo umano alle cellule tumorali e sulla traduzione delle terapie cellulari in pratica.
2seventy bio (Nasdaq: TSVT) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 7 de agosto de 2024. La empresa realizará una conferencia telefónica y una transmisión en webcast a las 8:00 a.m. ET para discutir los resultados. Los inversores pueden acceder a la llamada a través del webcast en el sitio web de la empresa o registrarse para obtener los detalles de la llamada. 2seventy bio es conocida por desarrollar la primer terapia con células CAR T aprobada por la FDA para el mieloma múltiple. El nombre de la empresa refleja su misión de trabajar a máxima velocidad (270 millas por hora) para dar a los pacientes con cáncer más tiempo. 2seventy bio se centra en comprender la respuesta inmunitaria del cuerpo humano a las células tumorales y en traducir las terapias celulares en práctica.
2seventy bio (Nasdaq: TSVT)는 2024년 2분기 재무 결과를 2024년 8월 7일에 발표할 것이라고 발표했습니다. 회사는 결과에 대해 논의하기 위해 동부 표준시 오전 8시에 컨퍼런스 콜과 웹캐스트를 개최합니다. 투자자들은 회사 웹사이트를 통해 웹캐스트에 접속하거나 전화 참여 세부 정보를 등록할 수 있습니다. 2seventy bio는 다발성 골수종을 위한 최초의 FDA 승인 CAR T 세포 치료법을 개발한 것으로 유명합니다. 이 회사 이름은 암 환자들에게 더 많은 시간을 제공하기 위해 최대 속도(시속 270마일)로 작업하겠다는 사명을 반영합니다. 2seventy bio는 종양세포에 대한 인체의 면역 반응을 이해하고 세포 치료법을 실천으로 옮기는 데 집중하고 있습니다.
2seventy bio (Nasdaq: TSVT) a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 7 août 2024. L'entreprise organisera une conférence téléphonique et un webinaire à 8h00 ET pour discuter des résultats. Les investisseurs peuvent accéder à l'appel via le webinaire sur le site internet de l'entreprise ou s'inscrire pour obtenir les détails de connexion. 2seventy bio est connue pour avoir développé la première thérapie CAR T approuvée par la FDA pour le myélome multiple. Le nom de l'entreprise reflète sa mission de travailler à la vitesse maximale (270 miles par heure) pour accorder plus de temps aux patients atteints de cancer. 2seventy bio se concentre sur la compréhension de la réponse immunitaire du corps humain aux cellules tumorales et sur la mise en pratique des thérapies cellulaires.
2seventy bio (Nasdaq: TSVT) hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am 7. August 2024 veröffentlichen wird. Das Unternehmen wird um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen. Investoren können über den Webcast auf der Unternehmenswebsite auf die Konferenz zugreifen oder sich für die Telefonteilnahme registrieren. 2seventy bio ist bekannt für die Entwicklung der ersten von der FDA zugelassenen CAR T-Zelltherapie für das multiple Myelom. Der Name des Unternehmens spiegelt sein Ziel wider, mit maximaler Geschwindigkeit (270 Meilen pro Stunde) zu arbeiten, um Krebspatienten mehr Zeit zu geben. 2seventy bio konzentriert sich darauf, die Immunantwort des menschlichen Körpers auf Tumorzellen zu verstehen und Zelltherapien in die Praxis umzusetzen.
- First FDA-approved CAR T cell therapy for multiple myeloma
- Focused mission on rapid translation of cell therapies
- None.
Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company’s website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event’s start. A replay of the call will be available on the 2seventy bio website following the completion of the call.
About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.
For more information, visit www.2seventybio.com.
Follow 2seventy bio on social media: X (Twitter) and LinkedIn.
2seventy bio is a trademark of 2seventy bio, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240805794829/en/
Investors:
Vicki Eatwell, CFO
vicki.eatwell@2seventybio.com
Jenn Snyder
Jenn.snyder@2seventybio.com
Media:
Jenn Snyder
Jenn.snyder@2seventybio.com
Source: 2seventy bio, Inc.
FAQ
When will 2seventy bio (TSVT) report its Q2 2024 financial results?
What time is 2seventy bio's (TSVT) Q2 2024 earnings call?
How can investors access 2seventy bio's (TSVT) Q2 2024 earnings call?
What is 2seventy bio's (TSVT) main product focus?
